Last reviewed · How we verify
Sequential and maintenance icotinib
Icotinib is a small-molecule tyrosine kinase inhibitor that selectively blocks epidermal growth factor receptor (EGFR) signaling to inhibit tumor cell proliferation.
Icotinib is a small-molecule tyrosine kinase inhibitor that selectively blocks epidermal growth factor receptor (EGFR) signaling to inhibit tumor cell proliferation. Used for Non-small cell lung cancer (NSCLC) with EGFR mutations.
At a glance
| Generic name | Sequential and maintenance icotinib |
|---|---|
| Also known as | Gemzar, DDP, Comana, BPI-2009 |
| Sponsor | Betta Pharmaceuticals Co., Ltd. |
| Drug class | EGFR tyrosine kinase inhibitor |
| Target | EGFR |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Icotinib irreversibly inhibits EGFR tyrosine kinase activity, preventing downstream signaling cascades that drive cell growth and survival in EGFR-dependent cancers. The sequential and maintenance dosing regimen is designed to optimize therapeutic efficacy while managing tolerability in patients with EGFR-mutant non-small cell lung cancer.
Approved indications
- Non-small cell lung cancer (NSCLC) with EGFR mutations
Common side effects
- Rash/dermatitis
- Diarrhea
- Nausea
- Elevated liver enzymes
- Fatigue
Key clinical trials
- Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma (PHASE4)
- Sequential and Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy in Advanced NSCLC (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: